CompletedNot Applicable

Assessment of Residual Paralysis in Patients Who Receive Mini-dose Atracurium During Supraglottic Airway Insertion

Singapore337 participantsStarted 2016-02

Plain-language summary

This study aims to establish the incidence of residual paralysis in patients following administration of a mini- dose of atracurium (less than ED95 i.e. \<0.23mg/kg or \<15 mg in most patients) during supraglottic airway insertion and correlate it with the duration of time from drug administration to arrival at PACU. The secondary aim is to compare the incidence of residual paralysis in patients who receive full doses of atracurium (per body weight) with those who receive mini-doses.

Who can participate

Age range21 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults above 21 years old * Received either a mini-dose of atracurium or full dose of atracurium during the placement of the supraglottic airway * Did not receive any neuromuscular reversal agent at any point of the operation. Exclusion Criteria: * Patients with underlying neuromuscular disease * Patients who received pre-operative medication that may affect neuromuscular transmission * Patients who required additional doses of neuromuscular blockade at any point of the operation

What they're measuring

Number of patients with Post operative residual paralysis as measured by Train of Four (TOF) Ratio of < 0.9

Timeframe: Through study completion, up to 4 months

Trial details

NCT IDNCT02673853

SponsorNational University Hospital, Singapore

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-03-08

View on ClinicalTrials.gov More Postoperative Complications trials